Whole-food based immune support
- Helps fight disease and infection
- Packed with immune boosters
- Reduces the risk of autoimmunity
- Promotes tissue healing
$43.06 — or subscribe and save 20%
Out of stock
Colostrum is occasionally and astutely known as ‘first milk’. It is produced in mammalian mammary glands in the latest stage of pregnancy and in the first few days after birth, and is quite simply the most important meal in one’s life. It is in effect a whole food that is minuscule in size yet extremely high in vital nutrients, growth factors and antibodies essential for the early development of newborn life.
Colostrum is responsible for triggering no fewer than fifty biochemical processes in a newborn’s body, which will provide the life-long foundation of the growth process and the immune system. Bovine colostrum is useful for boosting immunity, preventing autoimmunity, tissue healing, and as an agent for fighting infection and disease.
AOR‘s high-quality North American colostrum, derived from livestock raised under the best conditions and processed using the most rigorous quality control conditions, is the clear choice for purity and potency.
All-Life Colostrum is collected from North American cows exposed to severe temperature changes, which results in higher quality colostrum with higher immune factor concentration. All-Life Colostrum is purified of all but trace amounts of lactose and is freeze dried to preserve the activity of its unique proteins. All-Life Colostrum helps to support the immune system and immune function within the upper respiratory tract.
AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, nuts, peanuts, sesame seeds, sulphites, mustard, soy, eggs or shellfish.
Take one to 10 capsules daily with/without food, or as directed by a qualified health care practitioner.
Consult a health care practitioner for prolonged use or prior to use if you are pregnant or breastfeeding, have a history of cancer, diabetes, liver or kidney disease, an immune system disorder (e.g. Crohn’s disease, myasthenia gravis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, HIV/AIDS, etc.), are taking immunosuppressants or if you have been instructed to follow a low protein diet. Do not use if you have an allergy to dairy or cow’s milk.
Consult a health care practitioner for prolonged use or prior to use if you are pregnant or breastfeeding, have a history of cancer, diabetes, liver or kidney disease, an immune system disorder (e.g. Crohn’s disease, myasthenia gravis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, HIV/AIDS, etc.), are taking immunosuppressants or if you have been instructed to follow a low protein diet. Do not use if you have an allergy to dairy or cow milk.
- Immune enhancement
- Tissue repair/healing
- Muscle development
- Intestinal permeability (“leaky gut”)
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
†Also contains naturally occurring immunoglobulins G, M and A, lactoferrin and proline-rich peptides.
Non-medicinal Ingredients: Canola oil, Butylated hydroxytoluene, Sodium stearyl fumarate. Capsule: hypromellose.
In this randomized, placebo-controlled study, healthy volunteers received bovine colostrum or placebo daily for seven days, during which all participants were challenged with an attenuated salmonella typhi (Ty21a) oral vaccine to mimic an enteropathogenic infection. All participants were assessed for circulating antibody-secreting cells and the expression of phagocytosis receptors before and after oral immunization. The bovine colostrum supplemented groups showed a higher trend towards increases in specific IgA antibodies, compared to the placebo group, suggesting that colostrum may possess the potential to enhance human special immune responses.
Secretory IgA in saliva (s-IgA) is a potential mucosal immune correlate of upper respiratory tract infection (URTI) status. The aim of this randomized, double-blind, placebo-controlled study was to evaluate the effect, if any, of bovine colostrum or a placebo on s-IgA levels in male and female distance runners. Participants received supplementation or placebo for 12 weeks; saliva samples were taken prior to training at baseline, monthly during supplementation, and two week post supplementation.
The results show a 79% increase in the colostrum group after 12 weeks of supplementation, showing a physiological immune response of runners to bovine colostrum.
This randomized, placebo-controlled, double-blind study investigated the effect of bovine colostrum on mucosal defense in the respiratory tracts of athletes and a nonexercising control group. An athlete cohort of elite swimmers and control cohort were assigned to either a placebo or colostrum (25 g per day) supplementation group for 10 weeks. Postprandial saliva samples were analyzed for immunoglobulins (A, G and M) at baseline, four weeks and 10 weeks of supplementation, as well as two weeks post supplementation. Blood samples were analyzed for immunoglobulins and C-reactive protein at baseline, five weeks, and 10 weeks of supplementation, as well as two weeks post supplementation. Upper respiratory tract symptoms and the effect of exercise were also recorded.
After four weeks of supplementation, there were fewer reports of upper respiratory tract symptoms incidents, compared to the placebo and non-exercising cohort groups.
There are many anecdotal reports of the effect of bovine colostrum in preventing upper respiratory tract infections (URTI). Studies have looked at the effect of colostrum supplementation on immunoglobulin A (IgA), an antibody that is known to protect against URTIs. The aim of this randomized, placebo-controlled, double-blind study was to examine the effect of concentrated bovine colostrum in adult males. Participants received colostrum or controls (whey protein) for eight weeks. Since the incubation period for an URTI is up to five days, symptoms reported during the first week of supplementation were analyzed separately to preclude those arising from infection prior to study commencement.
During the subsequent seven weeks of supplementation, a significantly lower proportion of subjects consuming colostrum reported symptoms of URTI, compared to the control group. The researchers conclude that bovine colostrum may enhance resistance to the development of URTI symptoms.
This double-blind, placebo-controlled, randomized study evaluated the effect of bovine colostrum on viral upper respiratory tract infections in children with immunoglobulin A (IgA) deficiencies. Children were supplemented with either a placebo or bovine colostrum three times daily for 1 week and samples of saliva were obtained for IgA analysis before treatment, after administration of the first dose and after the last dose.
The results show a significantly lower infection severity score in the colostrum supplementation group, compared to the placebo group, although no change in IgA levels were observed, confirming the immune-supporting effect of bovine colostrum.
In two double-blind, placebo-controlled, randomized studies, healthy adults were supplemented with bovine colostrum to determine whether supplementation provided any protection against diarrhea, when challenged with enterotoxigenic Escherichia coli (ETEC). In the first study 30 participants received either placebo or bovine colostrum (400 mg, three times daily) with a bicarbonate buffer. In the second study, the participants were given bovine colostrum (400 mg) with or without the bicarbonate buffer OR bovine colostrum (200 mg) without buffer and compared to a placebo.
The results show a significant improvement in protection against diarrhea in the groups receiving colostrum, compared to the placebo groups. The researchers note that there were no significant differences between the groups being supplemented with bicarbonate buffer and without. These results led the researchers to conclude that bovine colostrum could be helpful in reducing the risk of travelers’ diarrhea.
Intestinal permeability has been implicated in many pathologies. The aim of this double-blind, controlled study was to evaluate the effect of bovine colostrum supplementaion on intestinal permeability parameters in a group of athletes (since IP can develop during vigorous athletic training). Participants were randomized to receive either a placebo (whey protein) or colostrium (500 mg) per day for 20 days and gut permeability status was assessed by differential absorption of lactulose and mannitol (L/M test) and stool zonulin concentration.
The results show that bovine colostrum supplementation decreased gut intestinal permeability and zonulin concentrations, compared to the placebo and baseline numbers, showing that colostrum is effective in decreasing intestinal permeability in increased risk groups.
A follow up, more recent study evaluated the effect of bovine colostrum in improving intestinal permeability in critically ill patients. There was a significant decrease in plasma endotoxins levels, as well as plasma levels of zonulin compared to the placebo. Additionally, the incidence of diarrhea in the colostrum group was significantly lower, providing additional evidence for the use of bovine colostrum in maintaining healthy gut integrity.
This study was aimed at examining the efficacy of colostrum enemas in the treatment of distal colitis using a randomized, double-blind, controlled protocol. Participants received either a placebo solution or colostrum enema twice daily for four weeks. Both groups also received mesalazine, a treatment for inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis, and disease activity was monitored at baseline, two weeks, and four weeks of supplementation.
Following four weeks of supplementation, the colostrum groups showed a mean reduction in symptom score, compared to the placebo group. There was histological score improvement in 62.5% of the colostrum participants, compared to the 33% in placebo.